2. Academic Validation
  3. Intraoperative MET-receptor targeted fluorescent imaging and spectroscopy for lymph node detection in papillary thyroid cancer: novel diagnostic tools for more selective central lymph node compartment dissection

Intraoperative MET-receptor targeted fluorescent imaging and spectroscopy for lymph node detection in papillary thyroid cancer: novel diagnostic tools for more selective central lymph node compartment dissection

  • Eur J Nucl Med Mol Imaging. 2022 Aug;49(10):3557-3570. doi: 10.1007/s00259-022-05763-3.
Pascal K C Jonker 1 2,  Madelon J H Metman 1,  Luc H J Sondorp 1 3,  Mark S Sywak 2,  Anthony J Gill 4 5 6,  Liesbeth Jansen 1,  Thera P Links 7,  Paul J van Diest 8 9,  Tessa M van Ginhoven 10,  Clemens W G M Löwik 11,  Anh H Nguyen 12,  Robert P Coppes 3 13,  Dominic J Robinson 14,  Gooitzen M van Dam 15 16,  Bettien M van Hemel 17,  Rudolf S N Fehrmann 18,  Schelto Kruijff 19
Affiliations

Affiliations

  • 1 Department of Surgery, University Medical Center Groningen, University of Groningen, Hanzeplein 1, Groningen, 9713, GZ, the Netherlands.
  • 2 Department of Endocrine Surgery and Surgical Oncology, Royal North Shore Hospital, St Leonards, Australia.
  • 3 Department of Biomedical Sciences of Cell & Systems - Section Molecular Cell Biology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • 4 Department of Anatomical Pathology, NSW Health Pathology, Royal North Shore Hospital, St Leonards, Australia.
  • 5 Sydney Medical School, University of Sydney, Sydney, Australia.
  • 6 Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, Royal North Shore Hospital, St Leonards, Australia.
  • 7 Department of Endocrinology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • 8 Department of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands.
  • 9 Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD, USA.
  • 10 Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • 11 Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, the Netherlands.
  • 12 Department of Pathology, Erasmus MC, Rotterdam, the Netherlands.
  • 13 Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • 14 Department of Otorhinolaryngology and Head and Neck Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • 15 Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • 16 AxelaRx/TRACER B.V, Groningen, the Netherlands.
  • 17 Department of Pathology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • 18 Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • 19 Department of Surgery, University Medical Center Groningen, University of Groningen, Hanzeplein 1, Groningen, 9713, GZ, the Netherlands. s.kruijff@umcg.nl.
PMID: 35389070 DOI: 10.1007/s00259-022-05763-3
Abstract

Purpose: Patients undergoing prophylactic central compartment dissection (PCLND) for papillary thyroid Cancer (PTC) are often overtreated. This study aimed to determine if molecular fluorescence-guided imaging (MFGI) and spectroscopy can be useful for detecting PTC nodal metastases (NM) and to identify negative central compartments intraoperatively.

Methods: We used a data-driven prioritization strategy based on transcriptomic profiles of 97 primary PTCs and 80 normal thyroid tissues (NTT) to identify tumor-specific antigens for a clinically available near-infrared fluorescent tracer. Protein expression of the top prioritized antigen was immunohistochemically validated with a tissue microarray containing primary PTC (n = 741) and NTT (n = 108). Staining intensity was correlated with 10-year locoregional recurrence-free survival (LRFS). A phase 1 study (NCT03470259) with EMI-137, targeting MET, was conducted to evaluate safety, optimal dosage for detecting PTC NM with MFGI, feasibility of NM detection with quantitative fiber-optic spectroscopy, and selective binding of EMI-137 for MET.

Results: MET was selected as the most promising antigen. A worse LRFS was observed in patients with positive versus negative MET staining (81.9% versus 93.2%; p = 0.02). In 19 patients, no adverse events related to EMI-137 occurred. 0.13 mg/kg EMI-137 was selected as optimal dosage for differentiating NM from normal lymph nodes using MFGI (p < 0.0001) and spectroscopy (p < 0.0001). MFGI identified 5/19 levels (26.3%) without NM. EMI-137 binds selectively to MET.

Conclusion: MET is overexpressed in PTC and associated with increased locoregional recurrence rates. Perioperative administration of EMI-137 is safe and facilitates NM detection using MFGI and spectroscopy, potentially reducing the number of negative PCLNDs with more than 25%.

Clinical trial registration: NCT03470259.

Keywords

Lymph node imaging; Molecular fluorescence-guided imaging; Papillary thyroid cancer; Spectroscopy.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-P991650
    Anti-PSMA1/7 Antibody